OR WAIT null SECS
Quotient Sciences’ facility expansion is designed to increase support for fully integrated drug development programs.
Quotient Sciences, a company specializing in accelerating drug development, recently announced the completion of its expansion to its Nottingham, United Kingdom, facility. The expansion is geared toward increasing the capacity of its early-phase formulation development capabilities for oral solid dosage forms. The goal of this, according to a Feb. 8, 2023 press release, is to increase support for the company’s fully integrated drug development programs.
“With these expanded capabilities, we can start formulation development work even earlier for our customers, allowing for projects to start faster and turnaround times to be reduced, which in turn will speed up development timelines,” said Andy Lewis, global vice-president, Integrated Pharmaceutical Services, Quotient Sciences, in the release. “Importantly, the new equipment and process trains are fully integrated with our existing capabilities, so at the appropriate point we can quickly transition drug programs downstream into [Good Manufacturing Practice] clinical trial manufacturing, saving our customers precious time in advancing innovative medicines into the clinic.”
“Quotient Sciences’ mission is to help get new medicines to patients faster and over the course of the last decade we’ve been investing in capabilities to support that,” said Mark Egerton, CEO, Quotient Sciences, in the release. “We place a great importance on supporting customer demand and will continue to actively increase our formulation tool kit to provide more integrated solutions under a single organization to streamline the outsourcing paradigm for our customers.”
Source: Quotient Sciences